Balsalazide Disodium

Manufacturer
Physicians Total Care, Inc.
Effective date
2010-05-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:11:31

Label at a glance#

ProductBalsalazide Disodium
Active ingredientBALSALAZIDE DISODIUM
Label structure16 sections

Indications and uses

Balsalazide Disodium Capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in adults. Safety and effectiveness of Balsalazide Disodium Capsules beyond 12 weeks in adults have not been established.

Dosage and administration

For treatment of active ulcerative colitis in adult patients, the usual dose is three 750 mg balsalazide capsules to be taken 3 times a day (6.75 g per day) for up to 8 weeks. Some patients in the adult clinical trials required treatment for up to 12 weeks. Balsalazide capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on applesauce. The entire drug/applesauce mi...

Storage and handling

Balsalazide Disodium Capsules are supplied as light orange opaque capsules containing 750 mg balsalazide disodium and "54 795" printed in black ink on the cap and body, containing a yellow-orange powder. Bottles of 280 NDC 54868-6137-0   Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Roxane Laboratories, Inc. Relabeling of ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Balsalazide Disodium Capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in adults. Safety and effectiveness of Balsalazide Disodium Capsules beyond 12 weeks in adults have not been established.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Adult Dose

SPL UNCLASSIFIED SECTION

For treatment of active ulcerative colitis in adult patients, the usual dose is three 750 mg balsalazide capsules to be taken 3 times a day (6.75 g per day) for up to 8 weeks. Some patients in the adult clinical trials required treatment for up to 12 weeks.

2.2 Administration Alternatives

SPL UNCLASSIFIED SECTION

Balsalazide capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on applesauce. The entire drug/applesauce mixture should be swallowed immediately; the contents may be chewed, if necessary, since contents of balsalazide are NOT coated beads/granules. Patients should be instructed not to store any drug/applesauce mixture for future use.

If the capsules are opened for sprinkling, color variation of the powder inside the capsules ranges from orange to yellow and is expected due to color variation of the active pharmaceutical ingredient.

Teeth and/or tongue staining may occur in some patients who use balsalazide in sprinkle form with food.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Balsalazide Disodium Capsules are available as light orange opaque capsules containing 750 mg balsalazide disodium and "54 795" imprinted in black ink on the cap and body, containing a yellow-orange powder.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients with hypersensitivity to salicylates or to any of the components of Balsalazide Disodium Capsules or balsalazide metabolites. Hypersensitivity reactions may include, but are not limited to the following: anaphylaxis, bronchospasm, and skin reaction.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Exacerbations of Ulcerative Colitis

SPL UNCLASSIFIED SECTION

In the adult clinical trials, 3 out of 259 patients reported exacerbation of the symptoms of ulcerative colitis.

Observe patients closely for worsening of these symptoms while on treatment.

5.2 Pyloric Stenosis

SPL UNCLASSIFIED SECTION

Patients with pyloric stenosis may have prolonged gastric retention of balsalazide capsules.

5.3 Renal

SPL UNCLASSIFIED SECTION

Renal toxicity has been observed in animals and patients given other mesalamine products. Therefore, caution should be exercised when administering balsalazide to patients with known renal dysfunction or a history of renal disease. [See 13 NONCLINICAL TOXICOLOGY (13.2)]

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Studies Experience

SPL UNCLASSIFIED SECTION

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adult Ulcerative Colitis

SPL UNCLASSIFIED SECTION

During clinical development, 259 adult patients with active ulcerative colitis were exposed to 6.75 g/day balsalazide in 4 controlled trials.

In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo.

Adverse reactions reported by 1% or more of patients who participated in the 4 well-controlled, Phase 3 trials are presented by treatment group (Table 1).

The number of placebo patients (35), however, is too small for valid comparisons. Some adverse reactions, such as abdominal pain, fatigue, and nausea were reported more frequently in women than in men. Abdominal pain, rectal bleeding, and anemia can be part of the clinical presentation of ulcerative colitis.

Table 1: Adverse Reactions Occurring In ≥ 1% of Adult Balsalazide Patients In Controlled Trials
Adverse ReactionBalsalazide 6.75 g/day (N=259)Placebo (N=35)
Abdominal Pain16 (6%)1 (3%)
Diarrhea14 (5%)1 (3%)
Arthralgia9 (4%)0%
Rhinitis6 (2%)0%
Insomnia6 (2%)0%
Fatigue6 (2%)0%
Flatulence5 (2%)0%
Fever5 (2%)0%
Dyspepsia5 (2%)0%
Pharyngitis4 (2%)0%
Coughing4 (2%)0%
Anorexia4 (2%)0%
Urinary Tract Infection3 (1%)0%
Myalgia3 (1%)0%
Flu-Like Disorder3 (1%)0%
Dry Mouth3 (1%)0%
Cramps3 (1%)0%
Constipation3 (1%)0%

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during post-approval use of balsalazide in clinical practice: myocarditis, pericarditis, vasculitis, pruritus, pleural effusion, pneumonia (with and without eosinophilia), alveolitis, renal failure,interstitial nephritis, pancreatitis, and alopecia.

Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to balsalazide.

Hepatic

SPL UNCLASSIFIED SECTION

Postmarketing adverse reactions of hepatotoxicity have been reported for products which contain (or are metabolized to) mesalamine, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, hepatocellular damage including liver necrosis and liver failure. Some of these cases were fatal; however, no fatalities associated with these adverse reactions were reported in balsalazide clinical trials. One case of Kawasaki-like syndrome which included hepatic function changes was also reported, however, this adverse reaction was not reported in balsalazide clinical trials.

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

In an in vitro study using human liver microsomes, balsalazide and its metabolites [5-aminosalicylic acid (5-ASA), N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), 4-aminobenzoyl-ß-alanine (4-ABA) and N-acetyl-4-aminobenzoyl-ß–alanine (N-Ac-4-ABA)] were not shown to inhibit the major CYP enzymes evaluated (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5). Therefore, balsalazide and its metabolites are not expected to inhibit the metabolism of other drugs which are substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Pregnancy Category B. Reproduction studies were performed in rats and rabbits at oral doses up to 2 g/kg/day, 2.4 and 4.7 times the recommended human dose based on body surface area for the rat and rabbit, respectively, and revealed no evidence of impaired fertility or harm to the fetus due to balsalazide disodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether balsalazide disodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when balsalazide is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Pediatric use information is protected by marketing exclusivity.

10 OVERDOSAGE

OVERDOSAGE SECTION

No case of overdose has occurred with balsalazide. A 3-year-old boy is reported to have ingested 2 g of another mesalamine product. He was treated with ipecac and activated charcoal with no adverse reactions.

If an overdose occurs with balsalazide, treatment should be supportive, with particular attention to correction of electrolyte abnormalities.

11 DESCRIPTION

DESCRIPTION SECTION

Each Balsalazide Disodium Capsule contains 750 mg of balsalazide disodium, a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid or 5-ASA), an anti-inflammatory drug. Each capsule of balsalazide (750 mg) is equivalent to 267 mg of mesalamine. Balsalazide disodium has the chemical name (E)-5-[[-4-[[(2-carboxyethyl) amino]carbonyl] phenyl]azo]-2-hydroxybenzoic acid, disodium salt, dihydrate. Its structural formula is:

structural formula
structural formula

Molecular Weight: 437.32

Molecular Formula: C17H13N3O6Na2•2H2O

Balsalazide disodium is a stable, odorless orange to yellow microcrystalline powder. It is freely soluble in water and isotonic saline, sparingly soluble in methanol and ethanol, and practically insoluble in all other organic solvents.

Inactive Ingredients: Each hard gelatin capsule contains ammonium hydroxide, colloidal silicon dioxide, FD&C Blue #1, FD&C Red #40, FD&C Yellow #6, gelatin, iron oxide black, isopropyl alcohol, magnesium stearate, n-butyl alcohol, propylene glycol, shellac, and titanium dioxide. The sodium content of each capsule is approximately 79 mg.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-ß-alanine carrier moiety. The carrier moiety released when balsalazide disodium is cleaved is only minimally absorbed and is largely inert.

The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-ASA diminishes inflammation by blocking production of arachidonic acid metabolites in the colon.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Balsalazide capsules contain a powder of balsalazide disodium that is insoluble in acid and designed to be delivered to the colon as the intact prodrug. Upon reaching the colon, bacterial azoreductases cleave the compound to release 5-ASA, the therapeutically active portion of the molecule, and 4-aminobenzoyl-ß-alanine. The 5-ASA is further metabolized to yield N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), a second key metabolite.

Absorption

SPL UNCLASSIFIED SECTION

The plasma pharmacokinetics of balsalazide and its key metabolites from a crossover study in healthy volunteers are summarized in Table 2. In this study, a single oral dose of balsalazide 2.25 g was administered to healthy volunteers as intact capsules (3 x 750 mg) under fasting conditions, as intact capsules (3 x 750 mg) after a high-fat meal, and unencapuslated (3 x 750 mg) as sprinkles on applesauce.

Table 2: Plasma Pharmacokinetics for Balsalazide and Key Metabolites (5-ASA and N-Ac-5-ASA) with Administration of Balsalazide Following a Fast, a High-Fat Meal, and Drug Contents Sprinkled on Applesauce (Mean ± SD)
Fasting (N=17)High-Fat Meal (N=17)Sprinkled (N=17)
Cmax (mcg/mL)
Balsalazide0.51 ± 0.320.45 ± 0.390.21 ± 0.12
5-ASA0.22 ± 0.120.11 ± 0.1360.29 ± 0.17
N-Ac-5-ASA0.88 ± 0.390.64 ± 0.5341.04 ± 0.57
AUClast (mcg·hr/mL)
Balsalazide1.35 ± 0.731.52 ± 1.010.87 ± 0.48
5-ASA2.59 ± 1.462.1 ± 2.582.99 ± 1.7
N-Ac-5-ASA17.8 ± 8.1417.7 ± 13.720 ± 11.4
Tmax (h)
Balsalazide0.8 ± 0.851.2 ± 1.111.6 ± 0.44
5-ASA8.2 ± 1.9822 ± 8.238.7 ± 1.99
N-Ac-5-ASA9.9 ± 2.4920.2 ± 8.9410.8 ± 5.39

A relatively low systemic exposure was observed under all three administered conditions (fasting, fed with high-fat meal, sprinkled on applesauce), which reflects the variable, but minimal absorption of balsalazide disodium and its metabolites. The data indicate that both Cmax and AUClast were lower, while Tmax was markedly prolonged, under fed (high-fat meal) compared to fasted conditions. Moreover, the data suggest that dosing balsalazide disodium as a sprinkle or as a capsule provides highly variable, but relatively similar mean pharmacokinetic parameter values. No inference can be made as to how the systemic exposure differences of balsalazide and its metabolites in this study might predict the clinical efficacy under different dosing conditions (i.e., fasted, fed with high-fat meal, or sprinkled on applesauce) since clinical efficacy after balsalazide disodium administration is presumed to be primarily due to the local effects of 5-ASA on the colonic mucosa.

In a separate study of adult patients with ulcerative colitis, who received balsalazide, 1.5 g twice daily, for over 1 year, systemic drug exposure, based on mean AUC values, was up to 60 times greater (0.008 mcg·hr/mL to 0.48 mcg·hr/mL) when compared to that obtained in healthy subjects who received the same dose.

Distribution

SPL UNCLASSIFIED SECTION

The binding of balsalazide to human plasma proteins was ≥99%.

Metabolism

SPL UNCLASSIFIED SECTION

The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces.

Elimination

SPL UNCLASSIFIED SECTION

Following single-dose administration of 2.25 g balsalazide (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.2%, 0.22% and 10.2%, respectively.

In a multiple-dose study in healthy subjects receiving a balsalazide dose of two 750 mg capsules twice daily (3 g/day) for 10 days, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.1%, 0%, and 11.3%, respectively. During this study, subjects received their morning dose 0.5 hours after being fed a standard meal, and subjects received their evening dose 2 hours after being fed a standard meal.

In a study with 10 healthy volunteers, 65% of a single 2.25 g dose of balsalazide was recovered as 5-ASA, 4-aminobenzoyl-ß-alanine, and the N-acetylated metabolites in feces, while <1% of the dose was recovered as parent compound.

In a study that examined the disposition of balsalazide in patients who were taking 3 to 6 g of balsalazide daily for more than 1 year and who were in remission from ulcerative colitis, less than 1% of an oral dose was recovered as intact balsalazide in the urine. Less than 4% of the dose was recovered as 5-ASA, while virtually no 4-aminobenzoyl-ß-alanine was detected in urine. The mean urinary recovery of N-Ac-5-ASA and N-acetyl-4-aminobenzoyl-ß-alanine comprised <16% and <12% of the balsalazide dose, respectively. No fecal recovery studies were performed in this population.

All pharmacokinetic studies with balsalazide are characterized by large variability in the plasma concentration versus time profiles for balsalazide and its metabolites, thus half-life estimates of these analytes are indeterminate.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

In a 24-month rat (Sprague Dawley) carcinogenicity study, oral (dietary) balsalazide disodium at doses up to 2 g/kg/day was not tumorigenic. For a 50 kg person of average height this dose represents 2.4 times the recommended human dose on a body surface area basis. Balsalazide disodium was not genotoxic in the following in vitro or in vivo tests: Ames test, human lymphocyte chromosomal aberration test, and mouse lymphoma cell (L5178Y/TK+/-) forward mutation test, or mouse micronucleus test. However, it was genotoxic in the in vitro Chinese hamster lung cell (CH V79/HGPRT) forward mutation test.

4-aminobenzoyl-ß-alanine, a metabolite of balsalazide disodium, was not genotoxic in the Ames test and the mouse lymphoma cell (L5178Y/TK+/-) forward mutation test but was positive in the human lymphocyte chromosomal aberration test. N-acetyl-4-aminobenzoyl-ß-alanine, a conjugated metabolite of balsalazide disodium, was not genotoxic in Ames test, the mouse lymphoma cell (L5178Y/TK+/-) forward mutation test, or the human lymphocyte chromosomal aberration test. Balsalazide disodium at oral doses up to 2 g/kg/day, 2.4 times the recommended human dose based on body surface area, was found to have no effect on fertility and reproductive performance in rats.

13.2 Animal Toxicology and/or Pharmacology

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Renal Toxicity

SPL UNCLASSIFIED SECTION

In animal studies conducted at doses up to 2000 mg/kg (approximately 21 times the recommended 6.75 g/day dose on a mg/kg basis for a 70 kg person), balsalazide demonstrated no nephrotoxic effects in rats or dogs.

Overdosage

SPL UNCLASSIFIED SECTION

A single oral dose of balsalazide disodium at 5 g/kg or 4-aminobenzoyl-ß-alanine, a metabolite of balsalazide disodium, at 1 g/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

14.1 Adult Studies

SPL UNCLASSIFIED SECTION

Two randomized, double-blind studies were conducted in adults. In the first trial, 103 patients with active mild-to-moderate ulcerative colitis with sigmoidoscopy findings of friable or spontaneously bleeding mucosa were randomized and treated with balsalazide 6.75 g/day or balsalazide 2.25 g/day. The primary efficacy endpoint was reduction of rectal bleeding and improvement of at least one of the other assessed symptoms (stool frequency, patient functional assessment, abdominal pain, sigmoidoscopic grade, and physician’s global assessment [PGA]). Outcome assessment for rectal bleeding at each interim period (week 2, 4, and 8) encompassed a 4-day period (96 hours). Results demonstrated a statistically significant difference between high and low doses of balsalazide (Figure 1). 

Figure 1: Percentage of Patients Improved at 8 Weeks

figure 1
figure 1

A second study, conducted in Europe, confirmed findings of symptomatic improvement.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Balsalazide Disodium Capsules are supplied as light orange opaque capsules containing 750 mg balsalazide disodium and "54 795" printed in black ink on the cap and body, containing a yellow-orange powder.

Bottles of 280
NDC 54868-6137-0
 

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]

SPL UNCLASSIFIED SECTION

Roxane Laboratories, Inc.


Relabeling of "Additional" barcode label by:
Physicians Total Care, Inc.
Tulsa, OK       74146

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

17.1 Important Precautions Regarding Balsalazide

SPL UNCLASSIFIED SECTION

  • Instruct patients not to take balsalazide if they have a hypersensitivity to salicylates (e.g., aspirin).
  • Patients should be instructed to contact their health care provider under the following circumstances:
    • If they experience a worsening of their ulcerative colitis symptoms.
    • If they are diagnosed with pyloric stenosis, because balsalazide capsules may be slow to pass through their digestive tract.
    • If they are diagnosed with renal dysfunction. Damage to the kidney has been observed in people given medications similar to balsalazide.

17.2 What Patients Should Know About Adverse Reactions

SPL UNCLASSIFIED SECTION

  • In adult clinical trials the most common adverse reactions were headache, abdominal pain, diarrhea, nausea, vomiting, respiratory infection, and arthralgia.
  • Inform patients that this listing of adverse reactions is not complete and not all adverse reactions can be anticipated. If appropriate, a more comprehensive list of adverse reactions can be discussed with patients.

17.3 What Patients Should Know About Taking Balsalazide with Other Medication

SPL UNCLASSIFIED SECTION

  • Based upon limited studies conducted in a test tube, balsalazide is not believed to interfere with other drugs by preventing how the liver functions. However, as the studies were limited in scope, you should always consult your doctor and discuss potential interactions prior to initiating any new drug.

10003708/04 Revised October 2010

©RLI, 2010

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Balsalazide Disodium Capsules, 750 mg

NDC 54868-6137-0

image of package label
image of package label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
885857balsalazide disodium 750 MG Oral CapsulePSN1
885857balsalazide disodium 750 MG Oral CapsuleSCD1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
BALSALAZIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8e3d9cc4-ed07-08af-508a-5f750e6cdb51Product name320260112
6c13b22c-b3ba-4127-b768-0132dd5ab0d1Product name120230829
34627c48-41a0-6950-dec1-e0baf87a4e18Product name220150914

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-6137-0Balsalazide Disodium280 in 1 BOTTLECAPSULE2801

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-6137BALSALAZIDE DISODIUM CAPSULE [PHYSICIANS TOTAL CARE, INC.]11 package rows20110321_3934dfa6-f2f7-4bdc-94fa-6c17224da61d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-6137-0EA - Each54868-61371fff4464-7204-42c9-985b-d63d4325797e12012-07-24
0054-0079-28EA - Each0054-0079d2bb7c9a-1533-44cd-8e0f-0aaf1ab9e31512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
BALSALAZIDE DISODIUMACTIVE INGREDIENT1XL6BJI0341
BALSALAZIDEACTIVE MOIETYP80AL8J7ZP1
AMMONIAINACTIVE INGREDIENT5138Q19F1X1
BUTYL ALCOHOLINACTIVE INGREDIENT8PJ61P6TS31
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD1
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA1
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A81
FERROSOFERRIC OXIDEINACTIVE INGREDIENTXM0M87F3571
GELATININACTIVE INGREDIENT2G86QN327L1
ISOPROPYL ALCOHOLINACTIVE INGREDIENTND2M4163021
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I301
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
SHELLACINACTIVE INGREDIENT46N107B71O1
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU41
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 15 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-613754868-6137-0
0054-0079

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 13 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
AMMONIAAMMONIA SOLUTION5138Q19F1XCAPSULE / ORAL0.01 mgExact identifier — unii+route+dosage form
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4CAPSULE / ORAL300 mgExact identifier — unii+route+dosage form
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3CAPSULE / ORAL0.02 mgExact identifier — unii+route+dosage form
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOACAPSULE / ORAL16 mgExact identifier — unii+route+dosage form
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE / ORAL26.3 mgExact identifier — unii+route+dosage form
GELATINGELATIN2G86QN327LCAPSULE / ORAL10932 mgExact identifier — unii+route+dosage form
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357CAPSULE / ORAL11 mgExact identifier — unii+route+dosage form
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii+route+dosage form
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE / ORAL72 mgExact identifier — unii+route+dosage form
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302TABLET, EXTENDED RELEASE / ORALNAExact identifier — unii+route
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE / ORAL7 mgExact identifier — unii+route+dosage form
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE / ORAL256.4 mgExact identifier — unii+route+dosage form
SHELLACSHELLAC46N107B71OCAPSULE / ORAL34.48 mgExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A077806-001BALSALAZIDE DISODIUMBALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A077806-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28d4dbc9d85df4…
2026-10-15 13:18:302026-09A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28c2088c7a36db…
2026-09-14 22:38:342026-08A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2884e616aacf4f…
2026-08-18 06:07:402026-07A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-283f01610625f2…
2019-09-15 20:21 UTC2019-09A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A077806-001BALSALAZIDE DISODIUM750MGCAPSULE / ORALAB2007-12-283bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A077806-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A077806-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A077806-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A077806-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077806-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077806-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A077806-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077806-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077806-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077806-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077806-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077806-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077806-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077806-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077806-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077806-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077806-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077806-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077806-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077806-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077806-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077806-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077806-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077806-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077806-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A077806-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077806-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077806-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077806-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A077806-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A077806-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077806-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077806-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077806-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077806-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077806-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077806-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077806-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A077806-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A077806-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Balsalazide DisodiumBALSALAZIDE DISODIUMHikma Pharmaceuticals USA Inc.a0498308-14b2-4456-8e13-795f6fc8ea302024-02-22Warnings, Adverse reactionsExact identifier
ndc (product): 0054-0079
c2df194f-9b49-423d-83eb-ac96ab9720793934dfa6-f2f7-4bdc-94fa-6c17224da61d2010-05-21Warnings, Adverse reactionsExact identifier
spl id: c2df194f-9b49-423d-83eb-ac96ab972079
spl set id: 3934dfa6-f2f7-4bdc-94fa-6c17224da61d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.